Liminatus Pharma regains Nasdaq listing compliance

The company states: “On May 29, 2025, Liminatus Pharma (LIMN) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025. On June 2, 2025, the Company filed the Form 10-Q with the U.S. Securities and Exchange Commission. On June 3, 2025, the Company received a letter from the Staff stating that the Company had regained compliance with the Listing Rule and that the matter is now closed.”